thalidomide sold brand names contergan thalomid among others oral medication used treat number cancers eg multiple myeloma graftversushost disease many skin disorders eg complications leprosy skin thalidomide used number hivassociated conditions use associated increased levels common side effects include sleepiness rash severe side effects include tumor lysis syndrome blood clots peripheral thalidomide known human teratogen carries extremely high risk severe lifethreatening birth defects administered pregnancy major human fetal abnormalities include skeletal deformities eg amelia absence legs andor arms absence bones phocomelia malformation limbs single dose thalidomide regardless dosage enough cause teratogenic thalidomide first marketed west germany available first released thalidomide promoted anxiety trouble sleeping tension morning initially thought safe pregnancy concerns regarding birth defects arose resulting removal market europe total number infants affected thalidomide use pregnancy estimated died around time survived limb eye urinary tract heart initial entry us market prevented frances kelsey reviewer birth defects caused thalidomide led development greater drug regulation monitoring many approved united states use treatment world health organizations list essential available generic thalidomide used firstline treatment multiple myeloma combination dexamethasone melphalan prednisone treat acute episodes erythema nodosum leprosum well maintenance bacterium causes tuberculosis tb related leprosy thalidomide may helpful cases standard tb drugs corticosteroids sufficient resolve severe inflammation used secondline treatment manage graft versus host disease aphthous stomatitis children prescribed conditions children including actinic prurigo epidermolysis bullosa evidence uses recommended third line treatment graftversushostdisease adults lack efficacy side effects observed clinical thalidomide used people trying conceive follow risk management program prevent individuals breastfeeding pregnant prescribing doctor required ensure contraception used regular pregnancy tests taken allergic thalidomide take used caution people chronic infections hiv hepatitis thalidomide causes birth us food drug administration fda regulatory agencies approved marketing drug auditable risk evaluation mitigation strategy ensures people using drug aware risks avoid pregnancy applies men women drug transmitted verification high risk thalidomide cause excessive blood clots also high risk thalidomide interfere production several types new blood cells creating risk infection via neutropenia leukopenia lymphopenia risks blood clot via thrombocytopenia also risk anemia via lack red blood cells drug also damage nerves causing potentially irreversible peripheral thalidomide several adverse cardiovascular effects including risk heart attacks pulmonary hypertension changes heart rhythm syncope bradycardia atrioventricular thalidomide cause liver damage severe skin reactions like syndrome tends make people sleepy creates risk driving operating machinery kills cancer cells cause tumor lysis syndrome thalidomide prevent addition common reported people adverse effects include tremor dizziness tingling numbness constipation peripheral common adverse effects reported people include confusion depressed mood reduced coordination heart failure difficulty breathing interstitial lung disease lung inflammation vomiting dry mouth rashes dry skin fever weakness sense expected pharmacokinetic interactions thalidomide medicines due neutral effects pglycoprotein cytochrome family may interact sedatives due sedative action bradycardic agents like betablockers due bradycardiainducing effects risk peripheral neuropathy may increased concomitant treatment thalidomide agents known cause peripheral risk venous thromboembolisms thalidomide seems increased patients treated oral contraceptives cytotoxic agents including doxorubicin melphalan concurrently thalidomide may interfere various contraceptives hence advised women reproductive age use least two different means contraception ensure child conceived taking eighteen cases overdoses reported doses grams none specific antidote overdose exists treatment purely precise mechanism action thalidomide known twentyfirst although efforts identify thalidomides teratogenic action generated research papers proposal plausible mechanisms primary mechanism action thalidomide analogs anticancer teratogenic effects known cereblon ligase thalidomide also binds acts antagonist androgen receptor hence nonsteroidal antiandrogen accordance produce gynecomastia sexual dysfunction side effects thalidomide provided racemic mixture two enantiomers reports one enantiomers may cause birth defects body converts enantiomer mechanisms well renantiomer desired sedative effect senantiomer harbors embryotoxic teratogenic effect attempting extract solely rthalidomide remove risk birth defects demonstrated safe rthalidomide undergoes vivo chiral inversion teratogenic sthalidomide biological conditions enantiomers interconvert bidirectional chiral inversion r vice thalidomide racemic sthalidomide bioactive form molecule individual enantiomers racemize due acidic hydrogen chiral centre carbon glutarimide ring bonded phthalimide substituent racemization process occur process conversion one enantiomer mirrorimage version change molecule called chiral celgene corporation originally synthesized thalidomide using threestep sequence starting lglutamic acid treatment since reformed use shown image ncarbethoxyphthalimide react lglutamine yield nphthaloyllglutamine cyclization nphthaloyllglutamine occurs using carbonyldiimidazole yields thalidomide celgene corporations original method resulted yield sthalidomide whereas twostep synthesis yields product pure thalidomide synthesised chemical industry basel found effect animals discarded acquired chemie grünenthal german company established soap maker world war ii ended address urgent market need heinrich appointed head discovery program based experience working german armys antiviral research preparing reagents work mueckters assistant wilhelm kunz isolated byproduct recognized pharmacologist herbert keller analog glutethimide sedative medicinal chemistry work turned improving lead compound suitable drug result thalidomide toxicity examined several animals drug introduced sedative never tested pregnant researchers chemie grünenthal found thalidomide particularly effective antiemetic inhibitory effect morning october company launched thalidomide began marketing trade name proclaimed wonder drug insomnia coughs colds period use medications pregnancy strictly controlled drugs thoroughly tested potential harm thousands pregnant women took drug relieve symptoms time drugs development scientists believe drug taken pregnant person could pass across placental barrier harm developing soon appeared reports abnormalities children born mothers using thalidomide late noticed peripheral neuritis developed patients took drug period time point thalidomide ceased provided initially considered safe drug responsible teratogenic deformities children born mothers used pregnancies prior third trimester november thalidomide taken market due massive pressure press experts estimate thalidomide led death approximately children serious birth defects children half west regulatory authorities east germany never approved one reason initially unobserved side effects drug subsequent approval west germany time drugs tested teratogenic effects tested toxicity rodents usual uk british pharmaceutical company distillers company biochemicals ltd subsidiary distillers co ltd part diageo plc marketed thalidomide throughout uk australia new zealand brand name distaval remedy morning sickness advertisement claimed distaval given complete safety pregnant women nursing mothers without adverse effect mother child outstandingly safe distaval prescribed nearly three years globally pharmaceutical companies started produce market drug license chemie grünenthal pharmaceutical companies marketing thalidomide countries least different trade names us representatives chemie grünenthal approached smith kline french skf glaxosmithkline request market distribute drug north america memorandum rediscovered archives fda shows part inlicensing approach smith kline french conducted animal tests ran clinical trial drug us involving people including pregnant researchers involved clinical trials skf noted even used high doses thalidomide could induce sleep micecitation needed administered doses times larger claimed chemie grünenthal sleep inducing researchers could still achieve hypnotic effect animals humanscitation needed completion trial based reasons kept hidden decades skf declined commercialize drug chemie grünenthal reached agreement william merrell company cincinnati ohio later richardsonmerrell part sanofi market distribute thalidomide throughout us fda refused approve thalidomide marketing distribution however drug distributed large quantities testing purposes american distributor manufacturer richardsonmerrell applied approval september needed official charge fda review frances oldham kelsey rely information company include test results richardsonmerrell called perform tests report results company demanded approval six times refused time nevertheless total children thalidomideinduced malformations born us oldham kelsey given presidential award distinguished service federal government allowing thalidomide approved sale canadas food drug directorate approved sale thalidomide prescription november many different forms sold kevadon produced william merrell company seeking approval thalidomide product released market april common variant horners talimol put market october two months talimol went sale pharmaceutical companies sent physicians letters warning risk birth march drugs banned canadian market directorate soon afterward physicians warned destroy israeli physician jacob sheskin administered thalidomide patient critically ill leprosy patient exhibited erythema nodosum leprosum enl painful skin condition one complications leprosy treatment attempted despite ban thalidomides use results favourable patient slept hours able get bed without aid upon awakening clinical trial studying use thalidomide leprosy soon thalidomide used brazilian physicians drug choice treatment severe enl since least cases thalidomide embryopathy recorded people born brazil since production dispensing prescription thalidomide strictly controlled requiring women use two forms birth control submit regular pregnancy tests despite cases thalidomide embryopathy least cases identified brazil million thalidomide pills distributed throughout brazil time period largely poor brazilians areas little access healthcare cases occurred despite controls fda approved drugs use treatment thalidomides potential causing birth defects drug may distributed tightly controlled conditions fda required celgene corporation planned market thalidomide brand name thalomid establish system thalidomide education prescribing safety steps oversight program conditions required program include limiting prescription dispensing rights authorized prescribers pharmacies keeping registry patients prescribed thalidomide providing extensive patient education risks associated drug providing periodic pregnancy tests women take world health organization stated recommend thalidomide leprosy due difficulty adequately controlling use due availability shortly teratogenic properties thalidomide recognized anticancer potential explored two clinical trials conducted people advanced cancer including people multiple myeloma trials little work done thalidomide cancer judah folkman pioneered studies role angiogenesis proliferation growth blood vessels development cancer early shown solid tumors could expand without surprised scientific world hypothesizing true blood next year published work showing biomarker angiogenesis higher people cancer especially high people blood cancers evidence emerged meanwhile member lab robert damato looking angiogenesis inhibitors discovered thalidomide inhibited effective suppressing tumor growth around time wife man dying multiple myeloma standard treatments failed called folkman asking antiangiogenesis folkman persuaded patients doctor try thalidomide doctor conducted clinical trial thalidomide people multiple myeloma third subjects responded results trial published new england journal medicine work done celgene others us food drug administration granted accelerated approval thalidomide combination dexamethasone treatment newly diagnosed multiple myeloma also evaluated whether thalidomide combined melphalan prednisone patients multiple myeloma combination drugs probably results increase overall late early children countries born deformities phocomelia consequence thalidomide severity location deformities depended many days pregnancy mother beginning treatment time sensitive window occurring approximately day day thalidomide taken day pregnancy caused central brain damage day would damage eyes day ears face day arms leg damage would occur taken day known exactly many worldwide victims drug although estimates range despite side effects thalidomide sold pharmacies canada disaster prompted many countries introduce tougher rules testing licensing drugs kefauver harris us directive medicines act united states new regulations strengthened fda among ways requiring applicants prove efficacy disclose side effects encountered fda subsequently initiated drug efficacy study implementation reclassify drugs already market us federal drug administration published clinical trial guideline excluded women childbearing potential early phases clinical trials practice led exclusion later trial phases fda guideline implemented response protectionist climate caused thalidomide us task force womens health concluded lack womens health research part due fda guideline compromised amount quality information available diseases treatments affecting led national institute health policy women beneficial included clinical thalidomide successfully marketed safer alternative barbiturates due successful marketing campaign thalidomide widely used pregnant women first trimester pregnancy however thalidomide teratogenic substance proportion children born thalidomide embryopathy babies born te died first surviving individuals middleaged report experiencing challenges physical psychological socioeconomic related te individuals born te frequently experience wide variety health problems secondary te health conditions include physical psychological conditions compared individuals similar demographic profiles born te report less satisfaction quality life overall access health care services also challenge people women particular experienced difficulty locating healthcare professionals understand embrace brand names include contergan thalomid talidex talizer neurosedyn distaval many research efforts focused determining thalidomide causes birth defects activities human body efforts develop safer analogs efforts find uses thalidomide exploration antiangiogenic immunomodulatory activities thalidomide led study creation thalidomide celgene sponsored numerous clinical trials analogues thalidomide lenalidomide substantially powerful fewer side effects except greater celgene received fda approval lenalidomide revlimid first commercially useful derivative revlimid available restricted distribution setting avoid use pregnancy studies conducted find safer compounds useful qualities another potent analog pomalidomide fda additionally apremilast approved fda march thalidomide analogs used treat different diseases used regimen fight two interest turned pomalidomide derivative thalidomide marketed celgene active antiangiogenic agent also acts immunomodulator pomalidomide approved february fda treatment relapsed refractory multiple received similar approval european commission august expected marketed europe brand name conclusive evidence thalidomide lenalidomide useful bring maintain remission crohns thalidomide studied phase ii trial kaposis sarcoma rare softtissue cancer commonly seen immunocompromised caused kaposis sarcomaassociated herpesvirus httpsenwikipediaorgwikithalidomide